FDA grants orphan status to two Lux products

The FDA has granted orphan drug designation to two of Lux Bioscience's investigational therapies.

Related Videos
Noninfectious uveitis, uveitic macular oedema: A synopsis of frontline therapies
Approaches for managing treatment of patients with endophthalmitis
ARMOR study: Evaluating antibiotic resistance in the treatment of staph infections
Investigating efficacy of OC-02 to stimulate the trigeminal nerve for the treatment of dry eyes
Related Content
© 2023 MJH Life Sciences

All rights reserved.